Efficacy of Sofosbuvir and Ledipasvir in Comparison to Sofosbuvir and Daclatasvir in Management of Egyptian Chronic Hepatitis C Patients
Afro-Egypt. j. infect. enem. dis
;
10(2): 163-173, 2022. tables, figures
Article
Dans Anglais
| AIM
| ID: biblio-1426649
ABSTRACT
In Egypt, the prevalence of hepatitis C virus (HCV) antibodies is the highest worldwide by 7.6%. Applying efficient treatment protocol on large scale could decrease HCV prevalence as well as disease burden.The aim of this study is to compare the efficacy of Sofosbuvir plus ledipasvir versus Sofosbuvir plus daclatasvir in management of chronic hepatitis C Egyptian patients with either easy to treat (naive patients with Child score A5)or difficult to treat (interferon experienced).
Texte intégral:
Disponible
Indice:
AIM (Afrique)
Sujet Principal:
Résultat thérapeutique
/
Hépatite C chronique
Type d'étude:
Guide de pratique
/
Étude observationnelle
/
Facteurs de risque
Limites du sujet:
Humains
langue:
Anglais
Texte intégral:
Afro-Egypt. j. infect. enem. dis
Année:
2022
Type:
Article
Institution/Pays d'affiliation:
2 Hepatology , Gastroenterology and Infectious Diseases Department ,Faculty f o of Medicine for Girls, AL-Azhar/EG
/
Hepatology , Gastroenterology and Infectious Diseases Department ,Faculty f o of Medicine for Girls/EG
/
Tropical Medicine Department , National Hepatology and Tropical Medicine R R Research Institute/EG
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS